96-Well Chromatin Immunoprecipitation (ChIP) Assay
Porvair Sciences has announced an application note describing the excellent results achievable from a new 96-well format version of its ChromaTrap chromatin immunoprecipitation (ChIP) assay technology.
Developments in the field of epigenetics are rapidly expanding as researchers elucidate the principles governing gene regulation through the in vivo dynamic binding of proteins to DNA. Key to this is the need to analyse large numbers of high and low abundant regulatory mechanisms to systematically map protein-DNA interactions following pathogen/disease stimulus.
Chromatin immunoprecipitation (ChIP) assays are used to study these associations and have been historically limited to large sample numbers, onerous washing steps resulting in valuable sample losses and low signal to noise coupled with poor reproducibility. This new application note details the use of Chromatrap 96 Pro-A, a 96-well plate, each well of which contains a solid phase rigid porous polymer, BioVyon, to which Protein A is chemically bound, allowing up to 96 ChIP assays to be run in parallel on the same plate.
To determine ease of use, experimental design flexibility and reproducibility in screening multiple epigenetic targets with Chromatrap 96, the binding efficiency and occupancy of common epigenetic marks (H3, H4, H3K4me3 and RNA pol II) on three gene targets of interest (GAPDH, beta-globin, and PABPC1) in three human chromatin samples (HepG2, HeLa and K562) were performed simultaneously on the 96-well plate and analysed using qPCR. The application note describes in detail the analytical methodology, data interpretation and statistical analysis, as well as the benefits of using the new Chromatrap 96 high throughput ChIP assay plate, which include multiple target screening, flexible experimental design, robust reproducibility, high data quality and automated liquid handling potential.
To download a copy of this new application note, click here.
For further information or to discuss your application with technical product specialists please contact Porvair Sciences on +44 1372 824 290 / [email protected]
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance